Could a simple shot replace IV drips for some cancer patients?
NCT ID NCT04606381
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This early-phase trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. The study involves 158 adults with advanced solid tumors (like lung or head and neck cancers) that have not responded to other treatments. Researchers are checking safety, side effects, and how the drug moves through the body to find the best dose and formulation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center
West Hollywood, California, 90048, United States
-
Chungbuk National University Hospital
Cheongju-si, 28644, South Korea
-
Community Health Network
Indianapolis, Indiana, 46256, United States
-
Langone Health at NYC University, NYU School of Medicine
New York, New York, 10016, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Royal Marsden Hospital
Sutton, SM2 5PT, United Kingdom
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Seoul National University Bundang Hospital
Seongnam-si, 13620, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, 03722, South Korea
-
The Christie Nhs Foundation Trust
Manchester, M20 4BX, United Kingdom
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
amivantamab (a bispecific antibody targeting EGFR and cMet)
What this could lead to
If successful, this could provide a more convenient, injection-based version of amivantamab for people with certain advanced cancers, potentially improving quality of life.
What could go wrong
This is an early phase 1b study, so safety and the right dose are still being figured out. It may not work as well as the IV version, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.